Unity Biotechnology
UBX was delisted on the 8th of July, 2025.
84 hedge funds and large institutions have $42M invested in Unity Biotechnology in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 18 increasing their positions, 28 reducing their positions, and 18 closing their positions.
303% more call options, than puts
Call options by funds: $1.08M | Put options by funds: $269K
0.8% less ownership
Funds ownership: 3.3% → 2.5% (-0.8%)
14% less funds holding
Funds holding: 98 → 84 (-14)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
36% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 28
50% less capital invested
Capital invested by funds: $83.8M → $42M (-$41.7M)
67% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$923K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$833K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$500K |
| 4 |
Renaissance Technologies
New York
|
+$452K |
| 5 |
Two Sigma Investments
New York
|
+$367K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$6.05M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.61M |
| 3 |
Morgan Stanley
New York
|
-$1.46M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$771K |
| 5 |
Millennium Management
New York
|
-$588K |
UBX Hedge Fund Activity: Q3 2021 in Review
84 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Unity Biotechnology (UBX) for Q3 2021, worth a combined $42M — down 50% from $83.8M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of UBX and 6 opened new positions — a net loss of 12 holders — while 28 trimmed existing stakes and 18 added.
The largest buyer was GSA Capital Partners, adding an estimated $923K. The largest seller was Baillie Gifford & Co, cutting an estimated $6.05M.
- 84 institutional investors held Unity Biotechnology (UBX) as of Q3 2021, down from 98 in Q2 2021.
- Funds reported $42M of Unity Biotechnology stock for Q3 2021, down 50% quarter-over-quarter.
- 6 funds opened new Unity Biotechnology positions in Q3 2021 and 18 closed out, a net change of -12 holders.
- The largest Unity Biotechnology buyer in Q3 2021 was GSA Capital Partners, an estimated $923K added.
- The largest Unity Biotechnology seller in Q3 2021 was Baillie Gifford & Co, an estimated $6.05M sold.
Based on aggregated 13F filings for Q3 2021.